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Abstract
Bacterial resistance has become a worldwide concern, particularly after the emergence of
resistant strains overproducing carbapenemases. Among these, the KPC-2 carbapene-
mase represents a significant clinical challenge, being characterized by a broad substrate
spectrum that includes aminothiazoleoxime and cephalosporins such as cefotaxime. More-
over, strains harboring KPC-type β-lactamases are often reported as resistant to available
β-lactamase inhibitors (clavulanic acid, tazobactam and sulbactam). Therefore, the identifi-
cation of novel non β-lactam KPC-2 inhibitors is strongly necessary to maintain treatment
options. This study explored novel, non-covalent inhibitors active against KPC-2, as putative
hit candidates. We performed a structure-based in silico screening of commercially available
compounds for non-β-lactam KPC-2 inhibitors. Thirty-two commercially available high-scor-
ing, fragment-like hits were selected for in vitro validation and their activity and mechanism
of action vs the target was experimentally evaluated using recombinant KPC-2. N-(3-(1H-
tetrazol-5-yl)phenyl)-3-fluorobenzamide (11a), in light of its ligand efficiency (LE = 0.28 kcal/
mol/non-hydrogen atom) and chemistry, was selected as hit to be directed to chemical opti-
mization to improve potency vs the enzyme and explore structural requirement for inhibition
in KPC-2 binding site. Further, the compounds were evaluated against clinical strains over-
expressing KPC-2 and the most promising compound reduced the MIC of the β-lactam anti-
biotic meropenem by four-fold.
Introduction
The emergence of KPC-2 class-A β -Lactamase (BL) carbapenemase, which confers resistance
to last resort carbapenems, poses a serious health threat to the public. KPC-2, a class A BL,
PLOS ONE | https://doi.org/10.1371/journal.pone.0203241 November 29, 2018 1 / 22
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Klein R, Linciano P, Celenza G, Bellio P,
Papaioannou S, Blazquez J, et al. (2018) In silico
identification and experimental validation of hits
active against KPC-2 β-lactamase. PLoS ONE 13
(11): e0203241. https://doi.org/10.1371/journal.
pone.0203241
Editor: Alessio Lodola, University of Parma, ITALY
Received: August 15, 2018
Accepted: November 6, 2018
Published: November 29, 2018
Copyright: © 2018 Klein et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper.
Funding: Funded by Fondo di Ricerca di Ateneo
UNIMORE (DT). The funders had no role in study
design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
uses a catalytic serine to hydrolyze the β-lactam ring. Specifically, the hydrolysis reaction pro-
ceeds through a series of steps involving: (i) the formation of a precovalent complex, (ii) the
conversion to a high-energy tetrahedral acylation intermediate, (iii) followed by a low-energy
acyl-enzyme complex, (iv) a high-energy tetrahedral de-acylation intermediate consequent to
catalytic water attack, and (v) finally the release of the hydrolyzed β-lactam ring product from
the enzyme. [1–6].
Notably to treat infections caused by bacteria that produce class A BLs, mechanism-based
inhibitors (i.e., clavulanic acid, sulbactam, and tazobactam) are administered in combination
with β-lactam antibiotics. However, strains harboring KPC-type β-lactamases are reported to
be resistant to available β-lactamase inhibitors. Moreover, because of KPC-2’s broad spectrum
of activity (which includes penicillins, cephalosporins, and carbapenems) treatment options
against KPC-2-producing bacteria are scarce, and “last-resort” carbapenems are ineffective as
well [7]. Therefore, studies directed to the discovery of novel, non β-lactam KPC-2 inhibitors
have multiplied in the last years. Recently, new drugs able to restore susceptibility to β-lactams
i.e. the novel inhibitor avibactam in combination with ceftazidime (CAZ) and RPX7009
(vaborbactam) with meropenem have been approved (Fig 1)[8–10].
As attention on KPC-2 rises, the number of crystal structures of its apo and complexed
form disclosed in the PDB has increased, making KPC-2 a druggable target for structure based
drug design efforts and for the study of novel, non β-lactam like inhibitors of this threatening
carbapenemase [9–12]
Recently, two crystal structures of the hydrolyzed β-lactam antibiotics cefotaxime and faro-
penem in complex with KPC-2 were determined (PDB codes 5UJ3, 5UJ4; Fig 2).[13]
Both ligands form hydrogen-bond interactions with their C4-carboxyl group to Ser130,
Thr235 and Thr237. The dihydrothiazine moiety of cefotaxime and the dihydrothiazole moiety
of faropenem forms π-π-stacking interactions with Trp105. In the apo-enzyme, this side chain
adopts two rotamers, upon binding of a ligand just one. Mutagenesis studies have shown the
importance of Trp105 in substrate recognition [7]. The faropenem ring nitrogen forms a
hydrogen-bond interaction with Ser130, whereas the ring nitrogen of cefotaxime a hydrogen
bond with Ser70. The aminothiazole ring of cefotaxime forms van-der-Waals contacts with
Leu167, Asn170, Cys238 and Gly239, while the oxyimino group and the hydroxyethyl group of
faropenem are solvent exposed (Fig 2).[13]
Fig 1. Chemical structure of avibactam, RPX7009, and compounds 9a and 11a.
https://doi.org/10.1371/journal.pone.0203241.g001
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Based on this and other structural information, we used a hierarchical screening cascade for
the discovery of non β-lactam like KPC-2 inhibitors. The selected 32 candidates, most of them
fragment-like, were then validated as hits against isolated recombinant KPC-2. Among the tested
compounds 9a, a benzothiazole derivative, and 11a, a tetrazole-containing inhibitor, showed the
highest activity against KPC-2 and behaved as competitive inhibitors of the targeted carbapene-
mase (Fig 1). Subsequently, compound 11a, in light of its promising ligand efficiency and chemis-
try, was selected to undergo chemical optimization for potency improvement and to explore
structural requirement for inhibition in KPC-2 binding site. Further, the obtained compounds
were evaluated against clinical strains overexpressing KPC-2 and the most promising compound
reduced the MIC of the β-lactam antibiotic meropenem by four fold.
Materials and methods
Pharmacophore hypothesis
A search for similar binding sites of KPC-2 was carried out using the online tool PoSSuM—
Search K [14,15]. Based on shared ligand interactions in the retrieved structures (Table 1), a
Fig 2. Structures and binding modes of hydrolyzed β-lactam antibiotics in the KPC-2 binding site. Left: binding mode of hydrolyzed cefotaxime (PDB code
5UJ3). Right: binding mode of hydrolyzed faropenem (PDB code 5UJ4). The second rotamer of Trp105 adopted in the apo-enzyme is coloured in beige, protein
side chains in blue and ligands in green. Hydrogen bonds are indicated as black dots.
https://doi.org/10.1371/journal.pone.0203241.g002
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pharmacophore was defined based on a K. pneumoniae KPC-2 protein structure (PDB code
3RXW) [16] and the ligand OJ6 of CTX-M-9 β-lactamase (PDB code 4DE1) [17]. The derived
pharmacophore contained a hydrogen-bond acceptor feature for interaction with Thr237,
Thr235 and Ser130, a hydrophobic feature for π-stacking with Trp105 and a hydrogen bond
acceptor feature for interactions with Asn132 (Fig 3).
Virtual screening
Our in-house MySQL-database of commercially available compounds was used as basis for
virtual screening. This database contains catalogues from the following suppliers: Apollo
Table 1. Result of PoSSuM Search K for similar binding sites. Structures with binding sites similar with structure
3RXW in complex with a non-covalent ligand were reported.
PDB-code Protein name Resolution Ref.
1 4BD0 E. coli β-lactamase TOHO-1 1.21 Å [18]
2 3G30 E. coli β-lactamase CTX-M-9a 1.80 Å [19]
3 4DE1 E. coli β-lactamase CTX-M-9a 1.26 Å [17]
4 4DDY E. coli β-lactamase CTX-M-9a 1.36 Å [17]
5 4DE3 E. coli β-lactamase CTX-M-9a 1.44 Å [17]
6 4DDS E. coli β-lactamase CTX-M-9a 1.36 Å [17]
7 4DE0 E. coli β-lactamase CTX-M-9a 1.12 Å [17]
8 4EUZ S. fonticola β-lactamase SFC-1 1.08 Å [20]
9 4DE2 E. coli β-lactamase CTX-M-9a 1.40 Å [17]
10 3G35 E. coli β-lactamase CTX-M-9a 1.41 Å [19]
11 3G32 E. coli β-lactamase CTX-M-9a 1.31 Å [19]
12 3G2Y E. coli β-lactamase CTX-M-9a 1.31 Å [19]
13 3G31 E. coli β-lactamase CTX-M-9a 1.70 Å [19]
https://doi.org/10.1371/journal.pone.0203241.t001
Fig 3. Pharmacophore hypothesis for KPC-2 ligands. Binding site of KPC-2 (PDB code 3RXW, blue) superimposed
with a fragment of the ligand OJ6 bound to CTX-M-9 β-lactamase (PDB code 4DE1, cyan) and pharmacophore
features (red: hydrogen-bond acceptor, orange: hydrophobic interaction feature, purple: hydrogen-bond donor)
(Ambler numbering) [21].
https://doi.org/10.1371/journal.pone.0203241.g003
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Scientific, Asinex, Chembridge, Chemdiv, Enamine, InterBioScreen, Key Organics, Life
Chemicals, Maybridge, MicroCombiChem, Otava, Peakdale, Sigma-Aldrich, Specs, Timtec,
Vitas-M laboratory, and Zylexa Pharma. The compounds were standardized and filtered for
compounds fulfilling the following lead-like criteria: between 10 and 25 heavy atoms, between
one and six hydrogen-bond acceptors, between one and three hydrogen-bond donors and a
clog P between -3 and 3. In addition, the complexity was limited by only including compounds
with less than 7 rotatable bonds and between 1 and 3 ring systems. Compounds containing
unwanted reactive or toxic functional groups were excluded as well [22].
In-house python scripts based on OpenEye’s OEChem toolkit (OEChem, version 2016.6.1,
OpenEye Scientific Software, Inc., Santa Fe, NM, USA) were used to charge, tautomerize and
stereoisomerize the selected compounds (scripts are available at https://github.com/
ruthbrenk/compound_preparation). Conformers were generated using OpenEye’s OMEGA
toolkit [23]. The pharmacophore filtering was carried out using Molecular Operating Environ-
ment (MOE, Chemical Computing Group). Compounds that passed the pharmacophore filter
were transformed into a format suitable for docking as described previously [24].
The crystal structure of K. pneumoniae KPC-2 (PDB code 3RXW) [16] was used as receptor
for docking. The ’protonate 3D’ tool of MOE was used to add polar hydrogen atoms to the
receptor, energy minimize their positions and to assign partial charges based on the AMBER
force field parameters. Water molecules and ligands (CIT and SR3) were deleted and the posi-
tion of the Ser69 side chain was energy minimized with the same force field parameters. The
structure was aligned with the crystal structure of E.coli CTX-M-9 (PDB code 4DE1) and the
ligand 0J6 was used to define spheres as matching points for docking. Grid-based excluded
volume, van-der-Waals potential and electrostatic potential as well as solvent occlusion maps
were calculated as described earlier [25,26].
The compounds were docked into the binding site of KPC-2 using DOCK3.6 [26–28].
Parameters for sampling ligand orientations were set as follows: bin size of ligand and receptor
were set to 0.4 Å, overlap bins were set to 0.2 Å and the distance tolerance for receptor and
ligand matching spheres was set to 1.5 Å. Each docking pose which did not overlap with the
receptor was scored for electrostatic and van-der-Waals complementarity and penalized
according to its estimated partial desolvation energy. For each compound, only the best-scor-
ing pose out of its tautomers, protonation states or ring alignments was saved in the final dock-
ing hit list. The docking hit list was filtered with the pharmacophore described above, keeping
the ligand positions rigid. Compounds passing this filter were ranked by their calculated ligand
efficiency [29,30] and inspected by eye.
Expression and purification of recombinant KPC-2
The blaKPC-2 gene was kindly provided by Prof. Sergei Vakulenko (University of Notre Dame
du Lac, Indiana, USA) and cloned as already reported [31] and transformed into competent E.
coli BL21 (DE3) cells for protein expression. 50 mL of Tryptic Soy Broth (TSB) (50 mg/L kana-
mycin) were inoculated with fresh colonies and grown at 37˚C. 4 mL of the overnight culture
was used to inoculate 1.3 L of TSB (50 mg/L kanamycin) grown at 37˚C with shaking to an
optical density of 0.5 measured at 600 nm. Then expression of recombinant bla gene was
induced by adding 1.0 mM IPTG (isopropyl-D-thiogalactopyranoside) and the cells were
again allowed to grow at 20˚C overnight. Bacteria were harvested by centrifugation at 4000
rpm for 20 minutes. The pelleted cells were resuspended in Tris-HCl 50 mM pH 7.4–7.5. Peri-
plasmatic proteins were extracted as reported in the pET System Manual (TB055 10th Edition
Rev. B 0403) and subsequently dialyzed in sodium acetate buffer (50 mM, pH 5.0). The protein
was conveniently purified in a single step using a Macro-Prep High S resin and eluted using
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sodium acetate 50 mM pH 5.0 and a sodium chloride (NaCl) linear gradient from 100 to 500
mM. The purified protein was dialyzed overnight in sodium phosphate buffer 50 mM, pH 7.0
[31,32].
Inhibition assays
The hydrolytic activity of KPC-2 was measured using the β-lactam substrates CENTA (100 uM,
KM 70 uM) or nitrocefin (114 uM, KM 36 μM) in reaction buffer consisting of 50 mM of PB at pH
7.0 at 25˚C with 0.01% v/v Triton X-100 to avoid compound aggregation and promiscuous inhibi-
tion.[33] Reactions were monitored using a Beckmann DU640 spectrophotometer at 405nM for
CENTA and 480 nM wavelength for nitrocefin [34]. The test compounds were synthesized as
described below or purchased from Enamine, TimTec, Vitas-M, ChemBridge, Otava, Life Chemi-
cals or Apollo Scientific and assayed without further purification. Compounds were dissolved in
dimethyl sulfoxide (DMSO) to a concentration of 25 mM and stored at -20˚C. The highest con-
centration at which the compounds were tested was up to 1 mM (depending on their solubility).
All experiments were performed in duplicate and the error never exceeded 5%. The reaction was
typically initiated by adding KPC-2 to the reaction buffer last. To control for incubation effects,
protein was added to the reaction buffer first, and the reaction was initiated by the addition of
reporter substrate after 10 minutes of enzyme-compound incubation. The results are reported in
Fig 4 and Fig 5.
Competitive inhibition mechanism and the Ki for compound 9a was determined by Line-
weaver–Burk (LB) and Dixon plots. For compound 11a, already reported as competitive inhib-
itor of the extended spectrum β-lactamase (ESBL) CTX-M15, the Ki was calculated by the
Cheng-Prusoff equation (Ki = IC50/(1+ [S]/KM) assuming competitive inhibition [35].
Synthetic procedures
All commercially available chemicals and solvents were reagent grade and were used without
further purification unless otherwise specified. Reactions were monitored by thin-layer chro-
matography on silica gel plates (60F-254, E. Merck) and visualized with UV light, cerium
ammonium sulfate or alkaline KMnO4 aqueous solution. The following solvents and reagents
have been abbreviated: ethyl ether (Et2O), dimethyl sulfoxide (DMSO), ethyl acetate (EtOAc),
dichloromethane (DCM), methanol (MeOH). All reactions were carried out with standard
techniques. NMR spectra were recorded on a Bruker 400 spectrometer with 1H at 400.134
MHz and 13C at 100.62 MHz. Proton chemical shifts were referenced to the TMS internal stan-
dard. Chemical shifts are reported in parts per million (ppm, δ units). Coupling constants are
reported in units of Hertz (Hz). Splitting patterns are designed as s, singlet; d, doublet; t, triplet;
q quartet; dd, double doublet; m, multiplet; b, broad. Mass spectra were obtained on a 6310A
Ion TrapLC-MS(n).
General procedure for the synthesis of sulfonamides 1-6b. To a solution of 3-(1H-tetra-
zol-5-yl)aniline (1 eq.) in DCM dry (25 mL) at room temperature and under nitrogen atmo-
sphere, pyridine (3 eq.) and the appropriate sulfonyl-chloride (1.2 eq.) were added. The
mixture was reacted at room temperature for 2–12 h. The reaction was quenched with aqueous
saturated solution of NH4Cl and acidified at pH 4 with aqueous 1N HCl. The aqueous phase
was extracted with AcOEt, and the organic phase washed with brine, dried over Na2SO4 and
concentrated. The crude was crystalized from MeOH or Et2O to give the desired product.
N-(3-(1H-tetrazol-5-yl)phenyl)-3-fluorobenzenesulfonamide (1b). Pale yellow solid
(150 mg, yield 47%). 1H NMR (400 MHz, DMSO-d6) δ 7.19 (dd, J = 2.2, 8.1 Hz, 1H), 7.33–
7.45 (m, 2H), 7.47–7.58 (m, 3H), 7.62 (d, J = 7.7 Hz, 1H), 7.76 (t, J = 1.8 Hz, 1H), 10.61 (s, 1H),
the H of tetrazole exchanges. MS m/z [M+H]+ 320.1; [M-1]- 318.0.
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N-(3-(1H-tetrazol-5-yl)phenyl)-3-nitrobenzenesulfonamide (2b). Pink solid (62%
yield). 1H-NMR (400 MHz, DMSO-d6) δ: 7.31 (ddd, J = 1.0, 2.3, 8.2 Hz, 1H), 7.51 (t, J = 8.0
Hz, 1H), 7.74 (dt, J = 1.2, 7.8 Hz, 1H), 7.82–7.96 (m, 2H), 8.18 (dt, J = 1.3, 7.9 Hz, 1H), 8.46
(ddd, J = 1.0, 2.3, 8.2 Hz, 1H), 8.54 (t, J = 2.0 Hz, 1H), 10.90 (s, 1H); the H of tetrazole
exchanges. 13C-NMR (DMSO-d6) δ: 117.35, 120.09, 123.04, 127.35, 129.17, 129.22, 129.69,
133.21, 136.59, 137.99, 139.81, 148.82, 154.28. MS m/z [M+H]+ Calcd for C13H10N6O4S: 346.0
Found: 347.2.
N-(3-(1H-tetrazol-5-yl)phenyl)-5-(dimethylamino)naphthalene-1-sulfonamide (3b).
White solid (31% yield). 1H NMR (400 MHz, DMSO-d6) δ 2.78 (s, 6H), 7.20 (dd, J = 1.5, 7.6 Hz,
1H), 7.24–7.38 (m, 3H), 7.39–7.65 (m, 3H), 8.27 (dd, J = 1.6, 7.5 Hz, 1H), 8.41 (ddd, J = 1.5, 7.5,
19.3 Hz, 2H), the H of tetrazole exchanges. MS m/z [M+H]+ Calcd for C19H18N6O2S: 394.1
Found: 395.1.
N-(4-(N-(3-(1H-tetrazol-5-yl)phenyl)sulfamoyl)phenyl)acetamide (4b). Pink solid
(52% yield). 1H NMR (400 MHz, DMSO-d6) δ 2.12 (s, 3H), 7.31 (ddd, J = 1.0, 2.3, 8.2 Hz, 1H),
7.44 (t, J = 7.9 Hz, 1H), 7.65–7.72 (m, 3H), 7.74–7.79 (m, 2H), 7.86 (t, J = 1.9 Hz, 1H), the H of
tetrazole exchanges. 13C NMR (100 MHz, DMSO-d6) δ 22.58, 118.86, 118.95, 122.60, 123.07,
126.32, 127.96, 128.87, 129.96, 133.69, 139.01, 142.97, 170.57. MS m/z [M+H]+ Calcd for
C15H14N6O3S: 358.1 Found: 359.2.
N-(3-(1H-tetrazol-5-yl)phenyl)quinoline-8-sulfonamide (5b). White solid (88% yield).
1H NMR (400 MHz, Acetone-d6) δ 7.28–7.42 (m, 2H), 7.59–7.90 (m, 4H), 8.03 (dt, J = 1.1, 1.8
Hz, 1H), 8.25 (dd, J = 1.5, 8.2 Hz, 1H), 8.42 (dd, J = 1.4, 7.3 Hz, 1H), 8.52 (dd, J = 1.8, 8.4 Hz, 1H),
9.21 (dd, J = 1.8, 4.3 Hz, 1H), 9.41 (s, 1H), the H of tetrazole exchanges. 13C NMR (100 MHz, Ace-
tone-d6) δ 117.35, 120.09, 123.01, 123.04, 125.55, 128.06, 129.17, 129.69, 129.79, 130.11, 133.27,
139.81, 140.02, 140.84, 149.72, 154.28. MS m/z [M+H]+ Calcd for C16H12N6O2S: 352.1 Found:
353.2.
N-(3-(1H-tetrazol-5-yl)phenyl)-4-chlorobenzenesulfonamide (6b). Light yellow solid
(93% yield). 1H NMR (400 MHz, Methanol-d4) δ 7.57 (t, J = 8.0 Hz, 1H), 7.74 (dt, J = 1.3, 7.9
Hz, 2H), 7.78–7.84 (m, 1H), 7.99 (d, J = 8.6 Hz, 2H), 8.06 (d, J = 8.6 Hz, 2H), 8.41 (t, J = 1.9
Hz, 1H), the H of tetrazole exchanges. 13C NMR (100 MHz, Methanol-d4) δ 117.35, 120.09,
123.01, 123.04, 125.55, 128.06, 129.17, 129.69, 129.79, 130.11, 133.27, 139.81, 140.02, 140.84,
149.72, 154.28. MS m/z [M+H]+ Calcd for C13H10ClN5O2S: 335.0, 337.0 Found: 336.1, 338.2.
Results and discussion
Virtual screening
The binding sites in the available KPC-2 crystal structures were analyzed to select a suitable
receptor for docking. Alignment and superposition of the binding site residues of the seven
available crystal structures of E. coli and K. pneumoniae KpKPC-2 revealed a rather rigid bind-
ing site with only Trp105 adopting two different rotamers, a closed conformation found
6-times and an open one, found two-times. In one structure, both rotamers were present (Fig
6). Thus, for virtual screening, the structure with the highest resolution was selected (K. pneu-
moniae KPC-2 in complex with the covalent inhibitor penamsulfone PSR-3-226 (PDB code
Fig 4. Inhibitory activity of compounds selected from virtual screening. [a]Assays were performed in duplicate
(errors were less than 5%) with CENTA as reporter substrate (100 μM, km 70 μM). Kinetic were monitored at 25˚ by
following the absorbance variation at λ = 405 nm. [b] If no IC50 has been measured, percent inhibition at the highest
tested concentration is given in parentheses. For example,> 0.50 (26%) implies that the highest concentration tested
was 0.50 mM; at this concentration, the enzyme was inhibited by 26%. Therefore, IC50> 0.50 mM. When % Inhibition
was below 10% No Inibition (NI) is reported. [c]Assays were run after 10’ incubation of the inhibitor with KPC-2.
Reaction was started by the addition of CENTA.
https://doi.org/10.1371/journal.pone.0203241.g004
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3RXW), 1.26 Å resolution). This structure contained both rotamers of Trp105. For virtual
screening, the closed conformation was chosen, as this is the most dominant conformation
upon ligand binding.
Only little diversity with respect to bound ligands was found in the KpKPC-2 structures. To
obtain a more detailed picture on key interactions and to derive a pharmacophore hypothesis,
PoSSuM—Search K was used to search for similar binding sites containing non-covalent ligands.
This resulted in thirteen structures (Table 1), all having tetrazoles or carboxylates derivatives
bound in the hydrophilic pocket formed by the amino acids corresponding to Thr235, Thr237,
Ser130 and Ser70 in KpKPC-2 (Fig 6). Seven of the contained ligands were fragment hits for E.coli
CTX-M class A extended spectrum β-lactamase (ESBL), and four were derivatives of the most
potent screening hit. Further, a structure of S. fonticola SFC-1 S70A β-lactamase in a non-covalent
complex with meropenem and one of E.coli Toho-1 R274N: R276N β-lactamase in complex with
a boronic acid were retrieved. Superposition of the binding site residues of KpKPC-2 (PDB code
3RXW) and the CTX-M β-lactamase structures gave rmsd values for the Cα atoms between 0.72
and 0.82Å, for superposition of KpKPC-2 and S. fonticola SFC-1 (PDB code 4EUZ) 0.28Å and
for superposition KpKPC-2 and E.coli Toho-1 (PDB code 4BD0) 0.73Å (Fig 7).
Based on the retrieved structures, a pharmacophore hypothesis was derived. All of the
ligands in these structures as well as the β-lactamase binding protein (PDB code 3E2L, 3E2K)
and the covalent ligand of the structure used as receptor, formed a hydrogen-bond with
Thr235 or Thr237. Accordingly, a hydrogen-bond acceptor at the corresponding ligand posi-
tion was considered to be crucial for binding (Fig 3). Further, in most of the structures the
ligands formed interactions with Trp105 (Ambler numbering) [21]. Therefore, this interaction
was also included in the pharmacophore hypothesis. Hydrogen-bond interactions to Asn130
were found in four structures (PDB codes 3RXW, 3G32, 3G30, 4EUZ) and included as well.
A hierarchical approach was adopted for virtual screening. First, our in-house database of
around five million purchasable compounds was filtered for lead-like molecules [22]. In the
second step, the obtained hits were screened with the above-described pharmacophore result-
ing in 44658 compounds. Out of these, 31122 compounds could be docked into the Kp KPC-2
binding site. Filtering these binding poses again with the pharmacophore resulted in 2894
compounds. These were divided into three clusters, depending on the functional group placed
in the hydrophilic pocket (tetrazoles, carboxylates, sulfonamides) and inspected by eye. Finally,
32 compounds were selected for hit validation (Fig 4).
Most of the selected chemotypes carried an anionic group, mainly a carboxylic group or its
bioisostere, the tetrazole ring. Candidates were predicted to orient the anionic side of their
moiety in the carboxylic acid binding site of KPC-2, delimited by Ser130, Thr235 and Thr237
and present in all serine-based β -lactamases. In the above mentioned site, in fact, binds the C
(3)4’ carboxylate of β-lactams antibiotics as well as the sulfate group of avibactam and the car-
boxylic group of other known BLs inhibitors [12,31,36–38].
Hit evaluation
The large majority of the selected candidates were fragment-like as defined by the “rule of
three” [39]. Dealing with fragments, potencies in the high micromolar to millimolar range
Fig 5. Inhibitory activity of 11a sulphonamide derivatives. [a]Assays were performed in duplicate (errors were less
than 5%) with nitrocefin (114.28 μM, Km 36 μM) as reporter substrate. Kinetic were monitored at 25˚ by following the
absorbance variation at λ = 485 nm. [b] If no IC50 has been measured, percent inhibition at the highest tested
concentration is given in parentheses. For example,> 1.0 (37%) implies that the highest concentration tested was 1.0
mM; at this concentration, the enzyme was inhibited by 37% and IC50> 1.0 mM. When % Inhibition was below 10%
No Inhibition (NI) is reported.
https://doi.org/10.1371/journal.pone.0203241.g005
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were thus expected as well as others important issues such as reaching the solubility limit when
testing the compounds and unpredictable precipitation in the employed assays conditions
[40,41]. In our hands, the required high concentrations for ligand testing could not always be
Fig 6. Binding site of KpKPC-2 (PDB code 3RXW) with ligand meropenem (green, PDB code 4EUZ). The receptor conformation used for docking is coloured in
blue, the rotamer of Trp105 not considered in the docking setup in beige (Ambler numbering) [21].
https://doi.org/10.1371/journal.pone.0203241.g006
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achieved due to solubility which might have resulted in false negatives, but their true incidence
is difficult to establish [42].
However, some of the tested molecules inhibited the hydrolytic activity of KPC-2 with low
millimolar potency and their favorable solubility allowed us to determine full IC50 and/or Ki
values. Among those, compounds 9a and 11a were the most promising compounds with
micromolar affinities (IC50 of 0.15 and 0.036 mM, translating to ligand efficiencies (LE) of 0.38
and 0.28 kcal/mol/non-hydrogen atom, respectively; Fig 4) and were thus further investigated.
Compound 9a was predicted to place its carboxylate group in proximity of the catalytic
Ser70, in the carboxylic acid binding site mentioned above, forming hydrogen bond interac-
tions with the side chains corresponding to amino acids Ser130, Thr235 and Thr237 (Fig 8).
Thr 237 in KPC-2 is known to be necessary for cephalosporinase and carbapenemase activity
and is involved in clavulanic acid, sulbactam and tazobactam recognition.[7] This position in
β-lactamases that do not have carbapenemase or extended-spectrum β-lactamase (ESBL) activ-
ity generally corresponds to an alanine. The side chain hydroxyl groups of Ser130 and Ser70
were predicted to form interactions with the nitrogen of the benzothiazole ring. The predicted
position of the aromatic system is well placed to establish ring-ring interactions with Trp105, a
residue involved, in turn, in the stabilization of β-lactams through mainly hydrophobic and
van der Waals interactions (centroids distances of 4.4 and 4.5 A between Trp105 and the thio-
phene and the benzene rings respectively) The role of Trp105 in substrate and inhibitor inter-
actions in KPC-2 β-lactamase has been deeply investigated being essential for hydrolysis of
substrates.[7] The methoxy group of the molecule is oriented towards a rather open and sol-
vent accessible area of the binging site and does not contact any of the surrounding residues.
Interestingly, the presence of the sulphur atom of the benzothiazole system seems critical for
Fig 7. Analysis of PoSSuM hits. Superposition of the KpKPC-2 binding site residues (PDB code 3RXW, green) with
the E.coli CTX-M-9 β-lactamase (PDB code 4DDS, blue), the S. fonticola SFC-1 β-lactamase (PDB code 4EUZ, beige)
and the E.coli TOHO-1 β-lactamase (PDB code 4BD0, cyan) (Ambler numbering) [21].
https://doi.org/10.1371/journal.pone.0203241.g007
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affinity as the related compound 19a, the benzimidazole analog, resulted 6-fold less active.
Similar, the presence of the carboxylic group appeared to be crucial as compound 32a, without
such a functionality, was 8-fold less active.
Fig 8. Predicted binding mode of compound 9a (beige) in the KpKPC-2 receptor (blue). Putative hydrogen bond interactions are indicated as black dots (Ambler
numbering)[21].
https://doi.org/10.1371/journal.pone.0203241.g008
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For compound 9a binding affinity and mode of inhibition was determined by using gradi-
ent concentrations of CENTA. Fitting of the obtained data showed that compound 9a behaves
as a competitive inhibitor with a determined Ki of 112.0 μM (Fig 9). Its binding affinity was
also determined towards other class A β-lactamases (IC50 vs CTX-M9 160 μM). For this com-
pound aggregating behavior was also excluded by dynamic light scattering experiment (data
not shown) [43]. Compound 9a with its fragment-like characteristic (MW 208.21, determined
Ki 112.0 μM, LE 0.38 kcal/mol/non-hydrogen atom) exerts an interesting activity vs KPC-2
and represents a very promising molecule to be directed to hit to lead optimization.
Among the 32 selected hits evaluated in vitro for their binding affinity vs KPC-2, compound
11a was the most active inhibitor with a micromolar affinity vs KPC-2 (determined IC50
36 μM, calculated Ki 14.8 μM, LE 0.28 kcal/mol/non-hydrogen atom).[35] The tetrazole ring
of compound 11a, a well-known bioisostere of the carboxylic group, was predicted to lie in the
hydrophilic pocket formed by Thr235, Thr237, Ser130 and Ser70, driving the binding of the
inhibitor in KPC-2 active site(Fig 10). The phenyl ring attached to the tetrazole was predicted
to be sandwiched between the Trp105 side with a distance compatible with weak hydrophobic
interactions and the backbone of Thr237. The amide group of 11a was oriented in the canoni-
cal site delimited by Asn132, Asn170 and in a further distance Glu166 where the R1 amide
side chain of β-lactams is known to bind. However, the amine linker and the second phenyl
ring in 11a were not predicted to form any specific interactions with the protein, except for the
amide nitrogen contacting the backbone of Thr237. The distal fluoro-benzene ring was ori-
ented at the entrance of the active site against two hydrophobic patches, one defined by
Leu167, closer, and the other by the backbone of Asn170, a residue critical for carbapenemase
activity.
Hit derivatization and evaluation
Compound 11a appeared to be the most promising compound for optimization. Despite its
small size, it has a potency in the low micromolar range (calculated Ki 14.8 μM) and a suitable
ligand efficiency (0.28 kcal/mol/non-hydrogen atom). Therefore, this compound was selected
to undergo chemical optimization for potency improvement and to investigate target binding
requirements for optimal inhibitor-enzyme interaction. The phenyl-tetrazole moiety, that was
predicted to strongly drive the binding, was retained unaltered, whereas structural modifica-
tions on the linker and on the distal aromatic ring were introduced in order to explore and
maximize the interactions with the pocket formed by Asn132, Asn170 and Leu167 (Fig 10).
Fig 9. Determination of binding affinity and mode of inhibition of compound 9a. (A) Lineweaver–Burk plot (A)
and Dixon slope plot (B).
https://doi.org/10.1371/journal.pone.0203241.g009
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Because the amide linker does not contact efficaciously the protein we chose to replace it with
a sulfonamide (Fig 11). We meant to target residues proximal to the opening of the active site
while investigating the potentiality for sulfonamide derivatives.
Fig 10. Predicted binding mode of compound 11a (beige) in the KpKPC-2 receptor (blue). Putative hydrogen bond interactions are indicated as black dots (Ambler
numbering)[21].
https://doi.org/10.1371/journal.pone.0203241.g010
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Sulfonamides are more stable towards hydrolysis than carboxyamides, possess an additional
hydrogen bonding oxygen atom and their NH is a strong hydrogen bond donor. In addition,
the dihedral angle ‘ω‘ OSNH measures around 90˚ compared with the 180˚ ‘ω‘ OCNH angle of
amide. Sulfonamides, in addition, have a non-planar configuration that could orient the distal
ring towards Leu167 and Asn170 (Fig 12). Therefore, the introduction of a sp3 geometry could
allow a more efficacious spanning of the active site compared to the planar amide [44]. More-
over, modeling suggested that the sulfonamide group could form an additional hydrogen
bond with Asn132 residue actively involved in substrate recognition and hydrolysis.
Further, we explored different substitutions on the sulfonamide linker to probe binding
interactions. Substituents with different electronic and steric properties (i.e. halogens, nitro,
sulfonamide, carboxylic acid, methyl, acetamide, amino groups) were inserted in the different
position of the aromatic ring. In addition, the benzene ring was replaced by heterocyclic or
extended benzofused systems such as benzimidazole, quinazolinone, naphthalene, or quino-
lone ring. Based on the availability of compound or building blocks, 6 compounds (1b-6b)
were synthesized and 8 compounds (7b-14b) were purchased to test our hypothesis (Fig 5).
The fourteen new compounds were tested in vivo vs clinical strains overproducing KPC-2 to
evaluate their ability to restore bacteria susceptibility to carbapenem meropenem (Table 2).
Compounds 1b-6b were synthesized in high yield (75–95% yield) and purity (>95%)
through direct reaction of 3-(1H-tetrazol-5-yl) aniline and the appropriate sulfonyl chloride in
dichloromethane at room temperature for 3 hours (Fig 13).
The derivatives of compound 11a were tested for KPC-2 affinity (Fig 5). However, their sol-
ubility limit in the assay condition was often a limitation in accurate affinity determination.
Overall, the compounds exhibited either weaker activities than 11a or were not active at all at
tested concentration. This data lets us confidentially affirm that the sulfonamide linker is not a
suitable group to optimize the affinity of this compound series.
The antimicrobial activity of the best hits 9a and 11a and their derivatives was studied in
bacterial cell cultures to investigate their ability to cross the outer membrane reaching the peri-
plasmic space, where KPC-2 is secreted and confined in Gram negative bacteria. Compounds
were tested for synergy with the β-lactam antibiotic meropenem against four K. pneumoniae
clinical strains, isolated from different patients at the Hospital Universitario Son Espases,
Palma de Mallorca, Spain. One of the four clinical strains was not a KPC-2 producer and was
susceptible to meropenem (strain Kpn (C-); MIC <0.25 ug/mL). The three additional strains
harbored the blaKPC-2 gene and were resistant to meropenem (Table 2). [32] Noteworthy
none of the tested compounds had intrinsic antibiotic activity (MIC >256 ug/mL), against the
employed strains, included the susceptible one. The results show that in most cases the com-
pounds were not able to reverse antibiotic resistance and did not showed synergism with mer-
openem. However, against strain Kpn 53A8 the MIC value was lowered by a factor of two
when meropenem was combined with compounds 32a, 1b, 2b, 5b and 6b while in combina-
tion with compound 11a the MIC value was reduced by 4 fold.
Fig 11. Design strategy for amide derivatives. Virtual Screening hit 11a (left), amine 1 (black) and the optimized part
of the molecule (red).
https://doi.org/10.1371/journal.pone.0203241.g011
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Conclusions
In this study two novel hits for KPC-2 were identified via an in-silico approach (compound 9
and 11a, Fig 4). Both of them had promising LEs with 0.38 and 0.28 kcal/mol/non-hydrogen
atom, resp. 14 tetrazole derivatives originating from 11a were designed, synthesized and evalu-
ated for their ability to inhibit KPC-2. We introduced chemical diversity on the distal part of
the inhibitor, choosing to keep unchanged the anchor tetrazole ring while modifying the
amide and the distal ring. The results suggest that a sulfonamide linker is neither suitable to
improve the potency of 11a nor the solubility of final compounds. Future optimization work
should instead rather concentrate on exploring secondary binding sites more distal from the
pocket that the screening hits are supposed to address [45]. If the amide functionally found in
Fig 12. Predicted binding mode of a sulfonamide derivative of compound 11a (beige) in the KpKPC-2 receptor (blue). Putative hydrogen bond interactions are
indicated as black dots (Ambler numbering)[21].
https://doi.org/10.1371/journal.pone.0203241.g012
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11a or alternative linkers are best suited remains to be explored. Nevertheless, two promising
hit compounds for KPC-2 were retrieved which can serve as starting points to derive more
potent inhibitors.
Although a decrease of potency in in vitro tests was registered for the designed and synthe-
sized chemical entities, as none of the compounds was able to trigger stronger interactions
with the open region of KPC-2 they were meant to target, this study yielded a better compre-
hension of the catalytic pocket of this enzyme. Our study provided a better understanding of
how challenging the target of additional, superficial, binding pockets is and how it could be
critical in designing inhibitors with improved potency, especially in area proximal to the active
site opening.
The (1H-tetrazol-5-yl)phenyl ring was most frequents among the high scoring candidates
in our in silico study, suggesting that this functionality is well suited to anchor ligands in the in
KPC-2 binding site. The rather weak affinity of the ligands hints that rest of the ligand, i.e. the
Table 2. In vitro interaction between meropenem and synthesized compounds vs K. pneumoniae clinical strains.
MIC[a] meropenem in combination with synthesized compounds (1:1 molar) [a, b, c]
(μg/mL)
Code Kpn (C-) Kpn 99D8 Kpn 53A8 Kpn 53A9
— <0.25 256 256 256
9a <0.25 256 256 256
11a <0.25 256 64 256
32a <0.25 256 128 256
1b <0.25 256 128 256
2b <0.25 256 128 256
4b <0.25 256 256 256
5b <0.25 256 128 256
6b <0.25 256 128 256
[a] Assays were conducted against four K. pneumoniae clinical strains isolated from different patients at the Hospital
Universitario Son Espases, Palma de Mallorca, Spain. MICs were determined according to EUCAST standards and
the presented values are the median of three independent experiments.
[b] Compounds were testes alone and showed no activity (MIC>256) in all cases.
[c] Strain C- is control K. pneumoniae and meropenem susceptible (MIC < 0.25 ug/ml)
https://doi.org/10.1371/journal.pone.0203241.t002
Fig 13. Reagents and conditions. a) aryl-sulfonyl chloride (1.2 eq.), pyridine (3 eq.), dry DCM, N2, r.t, 3 h, 75–95%
yield.
https://doi.org/10.1371/journal.pone.0203241.g013
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functional groups out of the center phenyl ring and the amide liker, need to be optimized to
increase potency. However, introducing a sulfonamide linker was detrimental for potency. We
hypothesize that the presence of a sulfonamide instead of an amide led to a rearrangement of
the ligand in the binding site to minimize steric hindrance, and thus resulted in the loss of key
interactions. These rearrangements can be particularly critical in non-covalent inhibitors like
ours that are not stabilized by a covalent interaction with the catalytic serine, as this type of
inhibitors are supposed to have lower residence times with respect to covalent β-lactamase
inhibitors (Fig 1). In designing larger and more potent inhibitors, additional secondary bind-
ing sites which have been found to be critical for affinity improvement need to be considered
[45].
The difficulties in optimizing the affinity of hit 11a for its target are also caused by the lack
of an accurate 3D structure of the complex. While reliable methods using docking can be
obtained, experimental confirmation of the binding modes is desirable to make sure that no
wrong tracks are followed [46]. In the case of compound 11a, we are more certain about the
position of the tetrazole moiety in the binding site due to the availability of crystal structures of
related targets with similar ligands (Table 1) while the placement of the substituent we
attempted to optimize is more tentative. Further structural work and medicinal chemistry
work is ongoing to significantly increase the potency of the most promising compound 11a in
vitro and in vivo and new chemistry is under evaluation for these derivatives, taking advantage
of other additional recognition sites in KPC-2.
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